|
業務類別
|
Biotechnology |
|
業務概覽
|
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron. |
| 公司地址
| 444 West Lake Street, Suite 1700, Chicago, IL, USA, 60606 |
| 電話號碼
| +1 312 416-8592 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.maiabiotech.com |
| 員工數量
| 13 |
| Mr. Jeffrey C. Himmelreich, M.B.A. |
Head, Finance and Principal Financial and Accounting Officer |
美元 240.00K |
08/04/2025 |
| Dr. Sergei M. Gryaznov, PhD |
Chief Scientific Officer |
美元 363.00K |
08/04/2025 |
| Dr. Vlad Vitoc, M.B.A.,M.D. |
Chairman of the Board, President and Chief Executive Officer |
美元 473.00K |
08/04/2025 |
|
|
| Mr. Jean-Manasse Theagene |
Independent Director |
08/04/2025 |
| Dr. Stan V. Smith, PhD |
Lead Independent Director |
08/04/2025 |
| Ms. Louie Ngar Yee |
Independent Director |
08/04/2025 |
| Mr. Cristian Luput |
Independent Director |
08/04/2025 |
| Mr. Ramiro Guerrero, J.D.,L.L.M. |
Independent Director |
08/04/2025 |
| Dr. Vlad Vitoc, M.B.A.,M.D. |
Chairman of the Board, President and Chief Executive Officer |
08/04/2025 |
| Mr. Steven M. Chaouki |
Independent Director |
08/04/2025 |
|
|
|
|
